---
canonical_name: Sildenafil
alternate_names: Sildenafil Citrate, Viagra, Revatio, UK-92480
canonical_topic: Sildenafil for Health & Longevity
short_topic_lc: sildenafil
creation_date: 2026-0925-1726
creator_ai_fullname: Opus 5.5
ep_keywords: PDE5 Inhibitors, Phosphodiesterase-5 Inhibitors, Erectile Dysfunction Medications
---

# Sildenafil for Health & Longevity  
<section id="top" markdown="1"></section>  
Evidence Review created on 09/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5

**Also known as:** Sildenafil Citrate, Viagra, Revatio, UK-92480

  
## Motivation

<!-- This section was written only after the rest of the document was completed, so that it reflects the full scope of the topic. -->

Sildenafil, best known by the brand name Viagra, is a prescription oral medication that helps blood vessels relax by blocking an enzyme that normally switches that relaxation off. It is approved for erectile problems in men and has been in wide use for more than 25 years. Because it acts on blood vessels throughout the body, it has drawn interest well beyond sexual health.

Erectile problems are often an early warning sign of blood vessel disease. Several large studies of prescription records have linked sildenafil use with fewer heart attacks, longer survival, and even lower rates of Alzheimer's disease. Whether these links reflect the drug itself or the kind of men who seek it out is still debated, and no controlled trial has yet tested these long-term outcomes.

This review examines the evidence for and against sildenafil as a tool for health and longevity: its effects on sexual function, the heart and blood vessels, and the brain, its side effects and drug interactions, the dosing approaches in use, and how its effects can be tracked over time.

**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**

  
## Recommended Reading

<!-- Search statement: On 2026-09-25 a real-time search was performed with the built-in WebSearch tool for "<expert> sildenafil / Viagra / PDE5 inhibitors" for each priority expert, followed by on-site searches: foundmyfitness.com/search (d-browser; "sildenafil" returned no results, "viagra" returned only a brief curated news-link story on retinitis pigmentosa and an unrelated Joe Rogan episode), chriskresser.com/?s= (d-browser and curl; "sildenafil" and "viagra" returned only unrelated podcast pages on PCOS and the placebo effect), lifespan.io/?s=sildenafil (curl; returned the 2021 Alzheimer's article and a 2024 UK Biobank drug-mortality article), peterattiamd.com (web search surfaced the 2025 erectile dysfunction and cardiovascular health article, which discusses PDE5 inhibitors in a single paragraph and is cited in Therapeutic Protocol, and podcast #260 with urologist Mohit Khera, whose show notes, retrieved with d-browser, list segments on the history and mechanisms of erectile dysfunction medications and on prescribing them; the podcast was chosen), hubermanlab.com (web search surfaced the Eisenberg and Malik episodes; the Eisenberg transcript discusses sildenafil by name), and lifeextension.com (magazine articles from 1998, 2007, 2013 and 2017 mention sildenafil only in passing while promoting supplements; the Erectile Dysfunction protocol page discusses PDE5 inhibition in depth and was chosen). PubMed was searched for narrative reviews; the Ghofrani 2006 review was selected. -->

This section lists expert and academic sources that give a high-level overview of sildenafil and the drug class it belongs to.

- [Dr. Michael Eisenberg: Improving Male Sexual Health, Function & Fertility](https://www.hubermanlab.com/episode/dr-michael-eisenberg-improving-male-sexual-health-function-fertility) - Andrew Huberman

  Stanford urologist Michael Eisenberg explains how sildenafil and related oral medications serve as first-line therapy for erectile dysfunction and why response depends on the health of the blood vessels.

- [Erectile Dysfunction](https://www.lifeextension.com/protocols/male-reproductive/erectile-dysfunction) - Shayna Sandhaus

  A referenced protocol from Life Extension, a supplement retailer, on how sildenafil blocks phosphodiesterase-5 (the enzyme ending penile blood vessel relaxation), why one-third of men do not respond, and which lifestyle strategies accompany it.

- [#260 ‒ Men’s Sexual Health: why it matters, what can go wrong, and how to fix it – Mohit Khera, M.D., M.B.A., M.P.H.](https://peterattiamd.com/mohitkhera/) - Peter Attia

  Urologist Mohit Khera covers the history and mechanism of the phosphodiesterase-5-blocking erectile dysfunction drugs that include sildenafil, how he prescribes them, and erectile problems as an early sign of heart disease.

- [Viagra Identified as a Candidate Drug for Alzheimer's](https://lifespan.io/viagra-identified-as-a-candidate-drug-for-alzheimers/) - Arkadi Mazin

  Summarizes the insurance-claims and patient-derived neuron study that nominated sildenafil as a candidate Alzheimer's drug, including the caveat that the association does not prove cause and effect.

- [Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond](https://pubmed.ncbi.nlm.nih.gov/16883306/) - Ghofrani et al., 2006

  A narrative review, co-authored by a Pfizer scientist, tracing sildenafil from a failed chest-pain drug to treatments for erectile dysfunction and lung-artery high blood pressure, plus possible future uses.

No directly relevant content on sildenafil was found from Rhonda Patrick (FoundMyFitness), whose site returned only a brief curated news link, or from Chris Kresser, whose site search returned only unrelated pages.

  
## Grokipedia

<!-- Search statement: On 2026-09-25 grokipedia.com was searched for "sildenafil". Tier 1, d-browser: the site search page (grokipedia.com/search?q=sildenafil) loaded but returned "Failed to search. Please try again."; d-browser then loaded the direct article URL grokipedia.com/page/Sildenafil, which returned the article titled "Sildenafil". d-fetch retrieval of the same page confirmed its content (pharmacology infobox, indications, mechanism). d-proxy-1 and d-proxy-2 were not needed. -->

- [Sildenafil](https://grokipedia.com/page/Sildenafil)

  An encyclopedia-style overview of sildenafil's pharmacology, approved uses, side effects, and development history, useful as a quick factual reference.

  
## Examine

<!-- Search statement: On 2026-09-25 examine.com was searched for "sildenafil". Tier 1, d-browser: examine.com/search/?q=sildenafil returned a "Vercel Security Checkpoint" bot wall ("Failed to verify your browser"). Tier 2, d-fetch: HTTP 429 (too many requests). Tier 3, d-proxy-1: the search page loaded and stated "Sorry, there are no search results for sildenafil." d-proxy-2 was not needed. -->

No Examine.com article on sildenafil exists. Examine.com does not typically cover prescription medications.

  
## ConsumerLab

<!-- Search statement: On 2026-09-25 consumerlab.com was searched for "sildenafil". Tier 1, d-browser: consumerlab.com/search/?q=sildenafil loaded (title "Latest Information About Sildenafil"); tier 2, d-fetch, retrieved the full result list. Results consisted of recall and warning notices for sexual enhancement supplements adulterated with undeclared sildenafil, product reviews of other supplements, and short reader questions about supplements; no dedicated review or article on sildenafil itself was listed. d-proxy-1 and d-proxy-2 were not needed. -->

No dedicated ConsumerLab.com article on sildenafil exists. ConsumerLab.com does not typically cover prescription medications; its sildenafil search results are recall notices for supplements found to contain hidden, undeclared sildenafil.

  
## Systematic Reviews

<!-- Search statement: On 2026-09-25 PubMed was searched for "sildenafil[ti] AND (systematic review[ti] OR meta-analysis[ti])" (59 results) and for phosphodiesterase-5 inhibitor reviews on mortality, cardiovascular outcomes, melanoma, optic neuropathy, Raynaud's phenomenon and dementia (86 results). Selection prioritized relevance to adult health, study size, recency and coverage of both the main benefit and the main harms; neonatal, pregnancy and retracted reviews were excluded. -->

These systematic reviews and meta-analyses (pooled analyses of multiple studies) cover sildenafil's main benefit, its harms, and its most studied repurposed uses.

- [Sildenafil for male erectile dysfunction: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/12076233/) - Fink et al., 2002

  Pools 27 randomized trials (6,659 men); the core efficacy estimate showing sildenafil roughly triples successful intercourse attempts versus placebo.

- [Oral sildenafil citrate (viagra) for erectile dysfunction: a systematic review and meta-analysis of harms](https://pubmed.ncbi.nlm.nih.gov/19592078/) - Tsertsvadze et al., 2009

  Pools 49 randomized trials on harms: more headache, flushing, indigestion and visual disturbance, but no excess serious adverse events.

- [Sildenafil and risk of Alzheimer disease: a systematic review and meta-analysis](https://pubmed.ncbi.nlm.nih.gov/40096550/) - Chua et al., 2025

  Pools five observational studies (885,380 people) linking sildenafil use to about half the Alzheimer's risk; no randomized evidence exists.

- [PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials](https://pubmed.ncbi.nlm.nih.gov/24534379/) - Zhuang et al., 2014

  Nine trials (612 patients): PDE5 (phosphodiesterase type 5, the enzyme sildenafil blocks) inhibition improved exercise capacity in weak-pump, not stiff-heart, failure.

- [Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review](https://pubmed.ncbi.nlm.nih.gov/24462476/) - Wang et al., 2014

  Four trials (545 patients): better walking distance and less clinical worsening in lung-artery hypertension, without a demonstrated mortality benefit.

  
## Mechanism of Action

Sildenafil blocks phosphodiesterase type 5 (PDE5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP, the messenger nitric oxide uses to relax smooth muscle in blood vessel walls). It amplifies an existing nitric oxide signal but cannot create one: in the penis, sexual stimulation must first release nitric oxide, so the drug is not an aphrodisiac.

PDE5 is abundant in penile tissue, lung arteries, and systemic blood vessels, explaining the drug's use in pulmonary arterial hypertension (high blood pressure in the lung arteries) and its small blood pressure–lowering effect. The proposed longevity-relevant actions — better endothelial function (health of the blood vessel lining), less heart muscle overgrowth, improved insulin action — all run through the same cGMP–protein kinase G (the enzyme that carries out cGMP's effects) pathway. A competing explanation holds that lower mortality among users reflects healthier men seeking treatment, not a drug effect.

**Key pharmacology:** about 41% of an oral dose reaches the bloodstream; levels peak at about 1 hour (2 hours after a high-fat meal), per a Pfizer-run study ([Nichols et al., 2002](https://pubmed.ncbi.nlm.nih.gov/11879254/)). Half-life is 3–5 hours; about 96% binds to blood proteins; tissue distribution is wide. Liver metabolism runs mainly through CYP3A4 (the liver enzyme that clears about half of all drugs) and secondarily CYP2C9 (a liver enzyme that clears many common drugs), yielding an active metabolite of half the potency. Selectivity is about 10-fold over PDE6 (the retina's light-signaling enzyme), explaining transient blue-tinged vision, and 80-fold or more over other PDE families.

  
## Historical Context & Evolution

Sildenafil (compound UK-92480) was synthesized at Pfizer's laboratories in Sandwich, England, around 1989 as a potential treatment for angina (chest pain caused by reduced blood flow to the heart). Early trials showed only a weak effect on angina, but volunteers reported stronger erections, and a small Pfizer study confirmed an enhanced erectile response ([Boolell et al., 1996](https://pubmed.ncbi.nlm.nih.gov/8858389/)). Pfizer, the manufacturer, funded and co-authored the pivotal trials, which showed large improvements in erectile function ([Goldstein et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9580646/)), and the US Food and Drug Administration approved Viagra in March 1998. Research then turned to the lungs: the Pfizer-funded SUPER-1 trial ([Galiè et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16291984/)) led to approval as Revatio for pulmonary arterial hypertension in 2005.

Interest in health optimization grew from three observations. Erectile problems often precede heart disease by years; sildenafil reversed heart muscle overgrowth in mice ([Takimoto et al., 2005](https://pubmed.ncbi.nlm.nih.gov/15665834/)); and large prescription databases linked use to fewer cardiovascular events, lower mortality, and less Alzheimer's disease. Opinion has also moved the other way. A large trial in heart failure with preserved pumping function was neutral ([Redfield et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23478662/)), and a carefully designed Medicare study found no dementia protection ([Desai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36330433/)). These findings narrow, rather than close, the questions. Generic versions reached US pharmacies in late 2017, and the United Kingdom allowed pharmacy sale without a prescription in 2018, making low-cost access widespread.

  
## Expected Benefits

<!-- Search statement: Before writing this section, a dedicated search of the complete benefit profile was performed on 2026-09-25 using PubMed (systematic reviews and randomized trials of sildenafil for erectile dysfunction, antidepressant-associated sexual dysfunction, female sexual arousal disorder, lower urinary tract symptoms, Raynaud's phenomenon, pulmonary arterial hypertension, heart failure, high altitude, insulin sensitivity, diabetic cardiomyopathy, small vessel disease, Alzheimer's disease, cardiovascular outcomes, mortality, adipose browning, muscle and mitochondrial disease), the Grokipedia article, and expert sources (Peter Attia, Huberman Lab, Life Extension, Lifespan.io). -->

### High 🟩 🟩 🟩

#### Erectile and Sexual Function

Sildenafil improves erection quality and the success of intercourse by amplifying the nitric oxide signal in penile blood vessels. A meta-analysis of 27 randomized trials (6,659 men; [Fink et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12076233/)) and the pivotal Pfizer-funded trial ([Goldstein et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9580646/)) show benefit across organic, psychological, and mixed causes. It also relieves antidepressant-associated sexual dysfunction in men ([Nurnberg et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12503977/)) and women ([Nurnberg et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18647982/)) in Pfizer-supported trials. In women with arousal disorders, a large Pfizer-run trial found no benefit ([Basson et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12150499/)).

**Magnitude:** 57% vs 21% of intercourse attempts successful, and 83% vs 45% of men with at least one success, sildenafil vs placebo ([Fink et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12076233/)).

#### Vascular Function and Blood Pressure

Blocking PDE5 in the blood vessel wall modestly lowers blood pressure and improves measures of vascular aging. A 2025 meta-analysis of 63 randomized trials (3,242 participants) pooled sildenafil with other drugs of its class, reporting lower systolic and diastolic pressure, lower pulse wave velocity (a measure of arterial stiffness), and better flow-mediated dilation (the artery's ability to widen) ([Zhang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41469737/)). Whether these small changes translate into fewer cardiovascular events has not been tested in trials.

**Magnitude:** Systolic blood pressure −2.8 mm Hg, diastolic −1.8 mm Hg, and flow-mediated dilation +2.5 percentage points vs placebo, pooled across drugs of the class ([Zhang et al., 2025](https://pubmed.ncbi.nlm.nih.gov/41469737/)).

#### Raynaud's Phenomenon ⭕️ Not Central to Health & Longevity

Raynaud's phenomenon (episodes of painful, white or blue fingers caused by artery spasm in the cold) improves with sildenafil through relaxation of finger arteries. A crossover trial of 50 mg twice daily cut attack frequency and duration and quadrupled capillary blood flow ([Fries et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16275885/)), and a meta-analysis of six trials of this drug class confirmed moderate benefit ([Roustit et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23426043/)). This bears on circulation disorders, often linked to autoimmune disease, rather than on longevity itself.

**Magnitude:** 35 vs 52 attacks and 581 vs 1,046 cumulative attack minutes over the treatment period, sildenafil vs placebo ([Fries et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16275885/)).

#### Exercise Capacity in Lung-Circulation and Heart Failure Conditions ⭕️ Not Central to Health & Longevity

By lowering lung vascular resistance, sildenafil improves walking capacity in pulmonary arterial hypertension, without shown mortality benefit (Pfizer-funded SUPER-1 trial, [Galiè et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16291984/); [Wang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24462476/)). Gains extend to heart failure with reduced ejection fraction (a weakened heart pump) ([Lewis et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17785618/); [Zhuang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24534379/)), not preserved ejection fraction (a stiff but normally pumping heart) ([Redfield et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23478662/)); altitude results in healthy people are inconsistent ([Ghofrani et al., 2004](https://pubmed.ncbi.nlm.nih.gov/15289213/); [Carter et al., 2019](https://pubmed.ncbi.nlm.nih.gov/31191974/)). This bears on specific lung and heart diseases, not longevity.

**Magnitude:** Six-minute walk distance +45 to +50 m vs placebo at 12 weeks in pulmonary arterial hypertension ([Galiè et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16291984/)); clinical worsening RR (relative risk, the event rate on treatment divided by that on placebo) 0.39 ([Wang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24462476/)); peak oxygen uptake +3.25 mL/kg/min vs placebo in reduced ejection fraction heart failure ([Zhuang et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24534379/)).

### Medium 🟩 🟩

#### Cardiovascular Events and All-Cause Mortality

Large prescription-record studies consistently link sildenafil and related drugs to fewer heart attacks, less heart failure, and longer survival, plausibly through better endothelial function. A meta-analysis of 16 cohort studies (1.26 million people) found fewer major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) and lower mortality ([Soulaidopoulos et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38777751/)); similar findings come from men after a heart attack ([Andersson et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28280146/)) and the UK Biobank ([Morin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39364726/)). Healthier, wealthier men are more likely to use these drugs, and no randomized trial has tested survival.

**Magnitude:** Major adverse cardiovascular events RR 0.78 and all-cause mortality RR 0.70 in users vs non-users ([Soulaidopoulos et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38777751/)).

#### Lower Urinary Tract Symptoms

In men with both erectile dysfunction and lower urinary tract symptoms from an enlarged prostate (weak stream, urgency, night-time urination), sildenafil improved urinary symptom scores alongside erectile function, probably by relaxing smooth muscle in the bladder neck and prostate. Evidence comes from one 12-week Pfizer co-authored randomized trial of 369 men ([McVary et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17296414/)). Urinary flow rate did not change, so the benefit is on symptoms rather than obstruction.

**Magnitude:** International Prostate Symptom Score (a validated 0–35 urinary symptom scale) −6.3 vs −1.9 points, sildenafil vs placebo ([McVary et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17296414/)).

### Low 🟩

#### Alzheimer's Disease Risk ⚠️ Conflicted

Insurance claims linked sildenafil to 69% lower Alzheimer's risk ([Fang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/35572351/)) and a UK PDE5-inhibitor cohort to less ([Adesuyan et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38324745/)), but a Medicare study against another drug's users found none ([Desai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36330433/)). The net reading is an unconfirmed signal, possibly inflated by user differences.

**Magnitude:** Pooled HR (hazard ratio, relative rate over time) 0.47 across five observational studies ([Chua et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40096550/)), versus HR 0.99 in the Medicare study comparing against another drug ([Desai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36330433/)).

#### Insulin Sensitivity

Three months of sildenafil 25 mg three times daily improved insulin sensitivity and lowered urine albumin in overweight adults with prediabetes ([Ramirez et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26580240/)). Evidence is one small trial measuring insulin sensitivity with a clamp test (a controlled glucose infusion) rather than glucose outcomes.

**Magnitude:** Insulin sensitivity index +1.84 units vs placebo; urine albumin-to-creatinine ratio fell from 12.7 to 6.8 μg/mg ([Ramirez et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26580240/)).

#### Heart Muscle Remodeling

In 59 men with early diabetic heart muscle disease, sildenafil 100 mg daily for three months improved heart contraction and reduced heart wall thickening on magnetic resonance imaging ([Giannetta et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22496161/)), echoing reversal of heart overgrowth in mice. This is one small trial using imaging measures.

**Magnitude:** Left ventricular torsion (the heart's wringing motion as it contracts) changed by −3.9° with sildenafil vs +2.1° with placebo, moving toward normal, and circumferential strain (how much the heart wall shortens around its circumference) improved by about 4.5 units vs placebo ([Giannetta et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22496161/)).

#### Brain Blood Flow in Small Vessel Disease

In 75 older adults with cerebral small vessel disease (damage to the brain's tiny arteries), three weeks of sildenafil increased brain blood flow and vessel reactivity but did not reduce pulsatility (beat-to-beat pressure swings) in brain arteries, the primary endpoint ([Webb et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38832504/)). Cognitive outcomes were not measured.

**Magnitude:** White matter perfusion (blood flow to the brain's deep connecting tissue) +1.8 to +2.1 mL/100 g/min vs placebo ([Webb et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38832504/)).

#### Colorectal Cancer Risk

Observational studies link PDE5 inhibitor use to less colorectal cancer, possibly via a stronger gut lining ([Bhagavathula et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34508301/)). A US veterans cohort found lower risk with higher cumulative sildenafil doses ([Sutton et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32568473/)). No trial has tested this; healthier users may explain part of it.

**Magnitude:** Pooled RR 0.85 for colorectal cancer in PDE5 inhibitor users, and 0.63 with continuous use, across four observational studies ([Bhagavathula et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34508301/)).

#### Mitochondrial Disease Symptoms ⭕️ Not Central to Health & Longevity

A drug screen in patient-derived brain cells identified sildenafil as a candidate therapy for Leigh syndrome (an inherited mitochondrial energy disease); it extended lifespan in animal models and improved motor function in six patients treated off-label ([Zink et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41819105/)). This bears on rare mitochondrial disease.

**Magnitude:** Motor function and resistance to metabolic crises improved in six patients with Leigh syndrome treated off-label; the literature reports no outcome figure for humans ([Zink et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41819105/)).

### Speculative 🟨

#### Browning of White Fat

Sildenafil caused heat-producing "browning" of white fat in mice ([Mitschke et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23303211/)) and raised UCP1 (a heat-generating protein) in overweight men ([Li et al., 2018](https://pubmed.ncbi.nlm.nih.gov/28986166/)). The basis is animal work and an unvalidated biomarker.

  
## Benefit-Modifying Factors

- **Genetic polymorphisms:** Small studies suggest variants in GNB3 (a gene for a cell-signaling protein; the 825T allele; [Sperling et al., 2003](https://pubmed.ncbi.nlm.nih.gov/12576843/)) and NOS3 (the gene for the vessel-wall nitric oxide enzyme) modify erectile response, but findings are inconsistent and unused clinically.
- **Baseline testosterone:** Men with low testosterone respond less well, because testosterone supports nitric oxide production in penile tissue; correcting clear deficiency can restore response in some non-responders.
- **Baseline vascular and metabolic markers:** Poor glucose control (high HbA1c, a three-month average blood sugar marker), smoking, and advanced atherosclerosis (artery plaque buildup) reduce erectile response, while the largest insulin and vascular gains were seen in people starting with prediabetes or endothelial dysfunction.
- **Sex:** Benefits in men are well established; in women, benefit is limited to antidepressant-associated sexual dysfunction and arousal disorder without low desire, while a broad female arousal disorder trial was negative ([Basson et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12150499/)).
- **Pre-existing conditions:** Diabetes, nerve-sparing prostate surgery, and spinal cord injury lower response rates. Heart failure benefit depends on type: reduced ejection fraction responds, preserved ejection fraction does not. Raynaud's phenomenon and pulmonary hypertension respond specifically.
- **Age:** Adults 65 and older have about 40% higher free drug levels, so lower doses often suffice. Erectile response declines with age mainly through vascular disease, and the mortality associations were seen in middle-aged and older men.

  
## Potential Risks & Side Effects

<!-- Search statement: Before writing this section, a dedicated search of the complete side effect profile was performed on 2026-09-25 using the US prescribing information for Viagra and Revatio (as summarized by drug references such as drugs.com and MedlinePlus), PubMed systematic reviews of harms (Tsertsvadze 2009, Fink 2002), and studies on nitrate interaction, optic neuropathy, melanoma, hearing loss, priapism, pregnancy use (Dutch STRIDER), and retinal effects. -->

### High 🟥 🟥 🟥

#### Headache, Flushing, Indigestion, and Nasal Congestion

These common adverse events follow from dilation of blood vessels in the head, skin, and nasal lining, and from relaxation of the lower esophageal sphincter (the muscle valve at the top of the stomach). A meta-analysis of 49 randomized trials found them consistently more frequent than with placebo and dose-related, but without excess serious adverse events ([Tsertsvadze et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19592078/)). Back pain, muscle aches, and nosebleeds occur less often. Most effects are mild, last a few hours, and often fade with continued use.

**Magnitude:** Flushing 12%, headache 11%, and indigestion 5% of users ([Fink et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12076233/)); any adverse event RR 1.56 vs placebo ([Tsertsvadze et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19592078/)).

#### Visual Disturbances

Sildenafil partly blocks PDE6 in the retina, causing transient blue-tinged vision (cyanopsia), light sensitivity, or blurring, mostly at 100 mg and above. Randomized trials consistently show more visual disturbance than placebo ([Tsertsvadze et al., 2009](https://pubmed.ncbi.nlm.nih.gov/19592078/)). The effect resolves within hours, and no lasting retinal harm has been shown in people with normal retinas.

**Magnitude:** Visual disturbances in 3% of users in pooled trials ([Fink et al., 2002](https://pubmed.ncbi.nlm.nih.gov/12076233/)).

#### Severe Low Blood Pressure With Nitrates

Nitrates (heart medications that release nitric oxide, such as nitroglycerin and isosorbide mononitrate) raise cGMP, and sildenafil stops its breakdown, so the combination can drop blood pressure sharply. Two Pfizer co-authored placebo-controlled crossover trials in healthy men and in men with stable angina confirmed this potentiation ([Webb et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10078539/); [Webb et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10898408/)). The result can be fainting, heart attack, or stroke in susceptible people, which is why the combination is contraindicated.

**Magnitude:** Standing blood pressure fell by 52/29 mm Hg with sildenafil plus isosorbide mononitrate vs 25/15 mm Hg with the nitrate alone ([Webb et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10898408/)).

### Medium 🟥 🟥

#### Newborn Lung Hypertension After Use in Pregnancy

In pregnancies with severe early fetal growth restriction, maternal sildenafil 25 mg three times daily did not improve outcomes and was associated with more persistent pulmonary hypertension in newborns (high lung blood pressure after birth), stopping the Dutch STRIDER trial early ([Pels et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32585017/)). The mechanism is thought to involve altered lung blood vessel development before birth. The finding comes from one randomized trial and applies to people who are or may become pregnant.

**Magnitude:** Newborn pulmonary hypertension 18.8% vs 5.1%, RR 3.67 ([Pels et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32585017/)).

### Low 🟥

#### Sudden Vision Loss (Optic Nerve Stroke) ⚠️ Conflicted

NAION (non-arteritic anterior ischemic optic neuropathy, an optic nerve stroke) was linked to recent doses in a Pfizer-sponsored self-comparison study ([Campbell et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25358826/)), not in a meta-analysis of users versus non-users ([Penedones et al., 2020](https://pubmed.ncbi.nlm.nih.gov/31559705/)), reflecting short-term versus overall risk. The net reading is a possible, rare risk.

**Magnitude:** About twofold higher odds (odds ratio, OR, the odds of the event with exposure divided by the odds without, 2.15) within five half-lives of a dose, estimated at 3 extra cases per 100,000 weekly users over 50 per year ([Campbell et al., 2015](https://pubmed.ncbi.nlm.nih.gov/25358826/)).

#### Melanoma ⚠️ Conflicted

A US cohort linked sildenafil to more melanoma ([Li et al., 2014](https://pubmed.ncbi.nlm.nih.gov/24710960/)), but the association lacked dose-response, appeared only for early-stage tumors, and extended to basal cell cancer, suggesting sun exposure and screening confound it ([Loeb et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29117385/)). The net reading is a weak, probably non-causal association.

**Magnitude:** Pooled RR 1.11 for melanoma across five observational studies ([Loeb et al., 2017](https://pubmed.ncbi.nlm.nih.gov/29117385/)).

#### Sudden Hearing Loss

Regulators added warnings for sudden sensorineural hearing loss (sudden inner-ear hearing loss) after post-marketing reports. A cross-sectional survey found self-reported hearing impairment more common in sildenafil users ([McGwin, 2010](https://pubmed.ncbi.nlm.nih.gov/20479381/)), but this design cannot establish cause.

**Magnitude:** OR 2.05 for self-reported hearing impairment among sildenafil users vs non-users ([McGwin, 2010](https://pubmed.ncbi.nlm.nih.gov/20479381/)).

#### Priapism

Priapism (a painful erection lasting over four hours, which can damage penile tissue) is reported with sildenafil, mostly in people under 18 or with sickle cell disease. Global pharmacovigilance data (adverse event reporting databases) show the signal in adults is weak ([Abbasi et al., 2024](https://pubmed.ncbi.nlm.nih.gov/37909414/)).

**Magnitude:** Priapism made up 0.41% of adverse reaction reports for this drug class; reporting odds ratio (how much more often priapism is reported for the drug than for comparison drugs) 1.08 for sildenafil in adults ([Abbasi et al., 2024](https://pubmed.ncbi.nlm.nih.gov/37909414/)).

### Speculative 🟨

#### Retinal Harm in Carriers of Inherited Retinal Disease

People with retinitis pigmentosa (an inherited retinal degeneration) or PDE6 gene mutations may be vulnerable to further PDE6 inhibition. The basis is mechanistic reasoning, animal data, and isolated reports.

  
## Risk-Modifying Factors

- **Genetic polymorphisms:** Inherited retinal disease involving PDE6 genes raises theoretical retinal risk. Reduced-function CYP3A4 or CYP2C9 variants may raise drug levels modestly; routine genotyping is not used.
- **Baseline blood pressure:** Resting pressure below 90/50 mm Hg, or orthostatic hypotension (a blood pressure drop on standing), raises the chance of fainting and dizziness; uncontrolled high pressure signals underlying vascular risk.
- **Sex:** Side effect profiles are similar in women and men. Pregnancy is the key female-specific risk, given the newborn lung hypertension signal.
- **Pre-existing conditions:** Coronary disease treated with nitrates, severe aortic stenosis (a narrowed heart valve), a crowded optic disc (small optic nerve head), prior NAION, severe liver or kidney disease, and bleeding disorders all raise risk.
- **Age:** Adults 65 and older reach about 40% higher drug levels and more often take nitrates, alpha-blockers (drugs that relax blood vessels and the prostate), or several blood pressure drugs, raising fall risk.

  
## Key Interactions & Contraindications

**Prescription drug interactions:**

- **Nitrates (nitroglycerin, isosorbide mononitrate, nicorandil):** Absolute contraindication; severe hypotension. A long-term Swedish registry linked co-use to higher mortality ([Trolle Lagerros et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38233015/)); a short-window Danish study found no acute-event rise ([Holt et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35436155/)). Mitigation: nitrates only ≥24 hours after a dose.
- **Soluble guanylate cyclase stimulators (drugs that directly raise cGMP: riociguat, vericiguat):** Contraindicated with riociguat and avoided with vericiguat; additive, potentially severe hypotension.
- **Alpha-blockers (doxazosin, terazosin, tamsulosin):** Caution; orthostatic hypotension, greatest with doxazosin. Mitigation: stable alpha-blocker dosing first, a 25 mg sildenafil start, and at least 4 hours between doses.
- **Strong CYP3A4 inhibitors (ritonavir, cobicistat, ketoconazole, itraconazole, clarithromycin):** Caution to avoidance; ritonavir raised sildenafil exposure 11-fold in a Pfizer-run study ([Muirhead et al., 2000](https://pubmed.ncbi.nlm.nih.gov/10930961/)), risking hypotension and more side effects. Mitigation: labeling limits sildenafil to 25 mg per 48 hours with ritonavir.
- **Moderate CYP3A4 inhibitors (erythromycin, fluconazole, diltiazem, verapamil):** Monitor; higher levels and more side effects. Mitigation: a 25 mg starting dose.
- **CYP3A4 inducers (drugs that speed its breakdown: rifampin, carbamazepine, phenytoin):** Monitor; reduced effectiveness. Mitigation: dose adjustment guided by response.
- **Blood pressure–lowering drugs (amlodipine, ACE inhibitors (drugs that block a blood pressure–raising hormone system; lisinopril), diuretics (drugs that increase urine output; hydrochlorothiazide)):** Monitor; additive 8/7 mm Hg reduction with amlodipine ([Webb et al., 1999](https://pubmed.ncbi.nlm.nih.gov/10078539/)). Mitigation: standing blood pressure checks after first doses.
- **Other PDE5 inhibitors (tadalafil, vardenafil, avanafil):** Caution; additive blood vessel widening and side effects. Mitigation: combined use only under specialist supervision.

**Over-the-counter medication interactions:**

- **Cimetidine (an acid reducer that inhibits drug metabolism):** Monitor; raises sildenafil levels by roughly half, increasing headache, flushing, and hypotension risk. Mitigation: a 25 mg starting dose, or famotidine as an alternative acid reducer.
- **Amyl or alkyl nitrite inhalants ("poppers"):** Absolute contraindication; they act like nitrates and can cause collapse.

**Supplement interactions:**

- **Nitric oxide boosters (L-arginine, L-citrulline, beetroot or dietary nitrate concentrates):** Monitor; additive blood vessel relaxation and lightheadedness. Mitigation: adding one product at a time with standing blood pressure checks.
- **Supplements with additive blood pressure–lowering effects (hibiscus, garlic extract, high-dose magnesium, omega-3 fatty acids):** Monitor; additive hypotension, usually small. Mitigation: blood pressure checks when combining.
- **St. John's wort:** Monitor; induces CYP3A4 and can reduce sildenafil levels and effect. Mitigation: dose adjustment guided by response, or avoiding the combination.
- **Horny goat weed (icariin) and yohimbine:** Caution; icariin adds weak PDE5 inhibition, yohimbine causes blood pressure swings and anxiety. Mitigation: avoiding use on sildenafil dosing days.
- **"Male enhancement" supplements:** Caution; many contain hidden sildenafil or analogues, risking unintended double dosing and nitrate reactions. Mitigation: avoiding unregulated sexual enhancement products entirely.

**Other interactions:**

- **Alcohol:** Monitor; heavy intake adds to blood pressure lowering and blunts erectile response. Mitigation: keeping intake to one or two drinks around dosing.
- **Grapefruit juice:** Monitor; inhibits intestinal CYP3A4, modestly raising sildenafil exposure and side effects and delaying onset. Mitigation: avoiding grapefruit juice around dosing.
- **Heat exposure (sauna, hot tub) and dehydration:** Monitor; additive blood vessel widening can cause dizziness. Mitigation: adequate hydration and standing up slowly.

**Populations who should avoid Sildenafil:**

- Anyone using nitrates, nitric oxide donors (sodium nitroprusside, molsidomine), nitrite inhalants, or riociguat
- Heart attack, stroke, or life-threatening arrhythmia (heart rhythm disorder) within the past 6 months
- Resting blood pressure below 90/50 mm Hg, or uncontrolled blood pressure above 170/110 mm Hg
- Unstable angina, or heart failure at NYHA Class IV (New York Heart Association top severity class: symptoms at rest)
- Prior NAION in either eye
- Retinitis pigmentosa or other hereditary retinal degeneration
- Severe liver impairment (Child-Pugh Class C, the most severe liver-function category) or end-stage kidney disease without specialist oversight
- Pregnancy, outside of specialist-managed pulmonary arterial hypertension
- Pulmonary veno-occlusive disease (blockage of the small lung veins)

  
## Risk Mitigation Strategies

- **Nitrate screen before every prescription:** Confirming that no nitrates, nitrite inhalants, or riociguat are used, and carrying a medication list, prevents the severe hypotension of this combination; emergency teams rely on knowing the last dose time.
- **Start low with older age or interacting drugs:** Starting at 25 mg for adults 65 and older, alpha-blocker users, and those on CYP3A4 inhibitors limits hypotension, dizziness, and falls; dose increases follow response over several doses.
- **Standing blood pressure check:** Measuring seated and standing blood pressure before and 1–2 hours after the first doses detects orthostatic hypotension early and guides dose changes.
- **Dose ceiling for visual effects:** Keeping to 50 mg or less where possible, and never exceeding 100 mg per day for on-demand use, reduces blue-tinged vision and light sensitivity, which rise sharply above 100 mg.
- **Stop-and-seek-care rules:** Sudden vision loss, sudden hearing loss, chest pain, or an erection lasting over 4 hours warrant stopping the drug and urgent care, limiting permanent optic nerve, inner-ear, or penile damage.
- **Eye and skin baseline:** A baseline eye exam for those with a crowded optic disc or retinal disease, and annual skin checks for those with melanoma risk factors, address the NAION and melanoma signals.
- **Licensed pharmacy sourcing:** Using prescription products from licensed pharmacies avoids counterfeit or adulterated products with unpredictable doses and contaminants.
- **Pregnancy planning:** Stopping sildenafil before trying to conceive, outside specialist pulmonary hypertension care, avoids the newborn lung hypertension risk seen in the Dutch STRIDER trial ([Pels et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32585017/)).

  
## Therapeutic Protocol

- **Conventional on-demand dosing:** 50 mg about 1 hour before sexual activity (range 25–100 mg), no more than once per 24 hours, per Pfizer's prescribing information and pivotal trial ([Goldstein et al., 1998](https://pubmed.ncbi.nlm.nih.gov/9580646/)); used in conventional urology.
- **Daily low-dose regimens:** Trials used 20 mg three times daily (pulmonary hypertension; [Galiè et al., 2005](https://pubmed.ncbi.nlm.nih.gov/16291984/)), 25 mg three times daily ([Ramirez et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26580240/)), or 100 mg once daily ([Giannetta et al., 2012](https://pubmed.ncbi.nlm.nih.gov/22496161/)). No longevity-specific regimen has been validated.
- **Competing approach, daily tadalafil:** Tadalafil 2.5–5 mg daily, an approved erectile regimen, gives steady coverage through its 17.5-hour half-life; [Peter Attia's team](https://peterattiamd.com/erectile-dysfunction-and-cardiovascular-health/) notes cohort data showing slightly stronger survival associations for tadalafil than sildenafil.
- **Integrative framing:** Integrative practitioners pair sildenafil with exercise, weight loss, glucose control, and testosterone assessment, as in the protocol of Life Extension (a supplement retailer that sells the add-on compounds it recommends); conventional urology treats it as on-demand symptom therapy.
- **Time of day:** On-demand doses are timed about 1 hour before activity on an empty stomach or light meal. Daily regimens are typically spread across the day; a single dose is often taken in the morning.
- **Half-life:** At 3–5 hours, sildenafil clears within about a day. Erectile effect lasts about 4–5 hours, and vascular effects wane between doses.
- **Single vs split dosing:** On-demand use is a single dose. Continuous vascular or pulmonary effects require split dosing, typically three times daily, because a single daily dose leaves long uncovered intervals.
- **Genetic considerations:** Retinitis pigmentosa or known PDE6 mutations argue against use. CYP3A4 and CYP2C9 variants have modest effects; no pharmacogenetic dosing test is established.
- **Sex-based differences:** Dosing is identical by sex in pulmonary hypertension. In women with antidepressant-associated sexual dysfunction, a trial used 50–100 mg before activity ([Nurnberg et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18647982/)); broader female use is off-label with weaker evidence.
- **Age:** From age 65, exposure rises about 40%, so 25 mg is a common starting dose, raised to 50 mg if tolerated and needed.
- **Baseline biomarkers:** Low testosterone, poor glucose control (high HbA1c), and low blood pressure predict weaker response or poorer tolerance; correcting deficiencies and measuring blood pressure first shapes dose choice.
- **Pre-existing conditions:** With severe kidney impairment (kidney filtering capacity under 30 mL/min) or liver cirrhosis, labeling specifies a 25 mg start. Diabetes and prostate removal surgery often mean 100 mg is needed for response.

  
## Discontinuation & Cycling

- **Duration of use:** Sildenafil can be used on demand indefinitely or daily for chronic conditions. There is no fixed endpoint; long-term vascular benefits, if real, would presumably require ongoing use.
- **Withdrawal effects:** No physical dependence or withdrawal syndrome is known. Stopping daily use in pulmonary arterial hypertension can worsen symptoms, so changes there are supervised.
- **Tapering:** No taper is needed for on-demand or low-dose use. In pulmonary arterial hypertension, specialists transition gradually to avoid rebound rises in lung pressure.
- **Cycling:** No evidence shows that cycling preserves effectiveness. Tolerance to the erectile effect has been reported anecdotally but is not established, so cycling is not a standard practice.
- **Temporary stops:** Pausing is standard before planned nitrate therapy, during acute chest pain evaluation, when starting strong CYP3A4 inhibitors, and before conception.

  
## Sourcing and Quality

- **Approved generic products:** Generic sildenafil citrate tablets (20, 25, 50, 100 mg) from regulated manufacturers such as Teva and Viatris deliver the same blood levels as brand Viagra and Revatio (Pfizer) and are inexpensive.
- **What to look for:** A licensed pharmacy, a prescription, intact packaging with lot number and expiry, and a regulator-approved manufacturer. Pharmacy verification tools (such as the US .pharmacy domain program) help confirm legitimacy of online sellers.
- **Compounded forms:** 503A and 503B compounding pharmacies (US pharmacies licensed to prepare custom or outsourced medications) supply oral suspensions and troches (dissolving lozenges); potency is less standardized than approved tablets, so pharmacies with independent potency testing offer more consistency.
- **Counterfeit and adulterated products:** "Herbal" sexual enhancement supplements are frequently recalled for hidden sildenafil or analogues, and counterfeit tablets sold online can contain wrong doses or contaminants.
- **Third-party testing:** Unlike supplements, approved sildenafil products are regulated drugs, so third-party testing is not needed; regulatory approval and pharmacy licensing provide quality assurance.

  
## Practical Considerations

- **Time to effect:** Erectile effects begin in 30–60 minutes and last about 4–5 hours. Urinary symptom and insulin changes emerged over 12 weeks of daily use in trials ([McVary et al., 2007](https://pubmed.ncbi.nlm.nih.gov/17296414/); [Ramirez et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26580240/)).
- **Common pitfalls:** Expecting an erection without sexual stimulation, dosing after a heavy fatty meal, judging failure after one or two attempts rather than six to eight at an adequate dose, heavy drinking, and buying unregulated online products.
- **Regulatory status:** Prescription-only in the United States; pharmacy sale without a prescription (Viagra Connect, 50 mg) is permitted in the United Kingdom. Use for longevity, vascular health, or cognition is off-label.
- **Cost and accessibility:** Generic sildenafil costs a few dollars or less per dose with discount programs. Insurers often cap erectile-use coverage but favor generic sildenafil over costlier pulmonary hypertension drugs, a financial incentive that may bias guidelines and research funding.
- **Telehealth access:** Many online prescribing services offer consultations and delivery; quality of medical screening varies, particularly for nitrate use and cardiovascular risk.

  
## Interaction with Foundational Habits

- **Sleep:** Indirect, potentially blunting. Headache and nasal congestion from evening doses can disturb sleep, and one small study suggested bedtime sildenafil may worsen severe untreated sleep apnea ([Roizenblatt et al., 2006](https://pubmed.ncbi.nlm.nih.gov/16983056/)). Practical considerations: daily doses earlier in the day, and sleep apnea treatment before starting, reduce these problems.
- **Nutrition:** Direct. A high-fat meal delays absorption by about an hour and blunts peak levels; grapefruit juice raises levels. A diet that improves endothelial function (vegetables, fiber, olive oil, limited processed food) supports the same nitric oxide pathway. Practical considerations: doses on an empty stomach or after a light meal act fastest.
- **Exercise:** Potentiating. Regular aerobic exercise improves endothelial function and erectile function independently, and the two likely add together. Sildenafil may help exercise in low oxygen but not in healthy people at sea level. Practical considerations: rising slowly after intense sessions limits lightheadedness.
- **Stress management:** Indirect. Sildenafil does not alter cortisol, but reliable erections can reduce performance anxiety, while chronic stress and anxiety reduce response. Practical considerations: pairing treatment with stress reduction or sex therapy benefits psychologically driven erectile problems.

  
## Monitoring Protocol & Defining Success

**Baseline testing:** Before starting, a cardiovascular risk assessment is commonly performed because erectile problems often signal vessel disease. Baseline tests include seated and standing blood pressure, a lipid and glucose panel, kidney and liver function (which set the starting dose), and, for men with erectile problems, morning testosterone. An eye exam is useful for those with retinal disease or prior vision loss.

**Ongoing monitoring:** Blood pressure (seated and standing) is rechecked 1–2 hours after the first doses and at 4 weeks. For daily users, labs are repeated at 3 months, then every 6–12 months; erectile function questionnaires are repeated at 4–8 weeks. Success is defined as improved symptom scores or vascular and metabolic markers without troublesome side effects.

| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|-----------|--------------------------|-----------------|---------------|
| Blood pressure (seated and standing) | Seated <120/80 mm Hg; standing drop <20/10 mm Hg | Detects hypotension risk | Conventional threshold for hypertension is ≥130/80 mm Hg; measure 1–2 hours post-dose on first use |
| ApoB | <80 mg/dL (<60 mg/dL for higher-risk individuals) | Cardiovascular risk baseline | ApoB (apolipoprotein B, the protein on each artery-clogging lipid particle); conventional reference range extends to about 130 mg/dL; conventional labs often report only LDL (low-density lipoprotein) cholesterol; fasting not required |
| HbA1c | <5.4% | Glucose control affects response | HbA1c (three-month average blood sugar marker); conventional normal is <5.7%; pair with fasting insulin |
| Fasting insulin | <6 µIU/mL | Tracks insulin sensitivity | Conventional reference ranges extend to about 25 µIU/mL; draw after an 8–12 hour fast, in the morning |
| eGFR | >90 mL/min/1.73 m² | Sets starting dose | eGFR (estimated glomerular filtration rate, a kidney function measure); conventional normal is ≥60; below 30 warrants a 25 mg start |
| ALT | <25 U/L | Liver clearance of the drug | ALT (alanine aminotransferase, a liver enzyme); conventional upper limit is about 40–55 U/L; pair with AST (aspartate aminotransferase, a second liver enzyme) |
| Total testosterone (men) | 500–900 ng/dL | Low levels blunt response | Conventional range is about 264–916 ng/dL; draw between 7 and 10 a.m., fasting |
| IIEF-5 score (men) | 22–25 | Tracks erectile function | IIEF-5 (International Index of Erectile Function, 5-item validated questionnaire); 21 or less indicates dysfunction; repeat at 4–8 weeks |
| hs-CRP | <1.0 mg/L | Vascular inflammation baseline | hs-CRP (high-sensitivity C-reactive protein, an inflammation marker); conventional labs flag cardiovascular risk only above 3.0 mg/L; no drug-specific target, so track change from the individual's own baseline; avoid testing during acute illness |

**Qualitative markers:**

- Erection quality and spontaneous morning erections
- Sexual satisfaction and confidence
- Exercise tolerance and breathlessness on exertion
- Urinary symptoms (stream, urgency, night-time urination)
- Headaches, flushing, and nasal congestion
- Vision changes (blue tinge, light sensitivity, blurring) and any hearing change
- Lightheadedness when standing

  
## Emerging Research

- **Peripheral artery disease (VIRTUOSE):** A phase 3, randomized, placebo-controlled trial testing sildenafil 140 mg each morning for 24 weeks in 106 adults with claudication (leg pain on walking from narrowed arteries); primary endpoint is absolute walking distance ([NCT03686306](https://clinicaltrials.gov/study/NCT03686306)). A positive result would strengthen the vascular case.
- **Chronic traumatic brain injury:** A phase 2 trial at the University of Pennsylvania enrolling 160 adults tests whether sildenafil improves damaged small brain vessels after head injury ([NCT05782244](https://clinicaltrials.gov/study/NCT05782244)), relevant to brain blood flow and cognitive aging.
- **Chronic obstructive pulmonary disease:** A phase 2 trial at the University of Alberta enrolling 160 adults tests oral sildenafil for exercise capacity, breathlessness, and heart-lung function in chronic obstructive pulmonary disease ([NCT05061368](https://clinicaltrials.gov/study/NCT05061368)).
- **Cancer-related cognitive impairment:** A planned phase 2/3 trial of 30 patients tests sildenafil to prevent fatigue and cognitive decline during cancer treatment ([NCT06800092](https://clinicaltrials.gov/study/NCT06800092)).
- **Alzheimer's disease prevention:** No randomized sildenafil prevention trial is registered. Claims-data signals ([Fang et al., 2021](https://pubmed.ncbi.nlm.nih.gov/35572351/)) conflict with a no-effect result from a study comparing users of another drug ([Desai et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36330433/)), and confounding by indication (healthier people being more likely to receive the drug) is a documented concern ([Wu & Swardfager, 2024](https://pubmed.ncbi.nlm.nih.gov/38995794/)).
- **Brain small vessel disease:** Improved brain perfusion (blood flow) without reduced pulsatility ([Webb et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38832504/)) calls for longer trials with cognitive and stroke outcomes.
- **Mitochondrial disease:** A stem-cell screen found sildenafil corrected mitochondrial defects, extended lifespan in animal models of Leigh syndrome, and helped six patients ([Zink et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41819105/)), opening questions about mitochondrial effects relevant to aging.
- **Survival signals needing trials:** UK Biobank data ([Morin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39364726/)) and cohort meta-analyses ([Soulaidopoulos et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38777751/)) associate use with longer life; a randomized outcome trial could confirm or refute causality.
- **Evidence that could weaken the case:** The neutral RELAX trial in heart failure with preserved ejection fraction ([Redfield et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23478662/)) and the higher mortality with combined nitrate use ([Trolle Lagerros et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38233015/)) show benefits are population-specific.

  
## Conclusion

Sildenafil is an inexpensive, well-characterized oral medication that strengthens the body's own blood vessel–relaxing signal. For health-focused adults, its best-established benefit is a reliable improvement in erectile and sexual function, supported by many controlled trials. It also has solid trial support for certain circulation problems, such as cold-triggered finger spasms and high blood pressure in the lungs, and it modestly improves measures of blood vessel health.

The longevity case rests on a different kind of evidence. Large prescription-record studies consistently link use to fewer heart attacks and longer survival, but men who obtain these drugs tend to be healthier and wealthier, and no controlled trial has tested survival. Signals for protection against Alzheimer's disease, better insulin action, and improved brain blood flow are early, and for dementia they are contradictory.

The main side effects are common and short-lived: headache, flushing, indigestion, congestion, and blue-tinged vision. The firmest serious risks are a dangerous blood pressure drop when combined with nitrate heart medications and, with use in pregnancy, high lung blood pressure in newborns; links to sudden vision loss, melanoma, and hearing loss remain uncertain and, if real, rare.

Much of the core effectiveness and safety evidence was funded or co-authored by the manufacturer, one integrative protocol comes from a supplement seller, and insurers' coverage limits may dampen funding for longer-term research. Overall, sildenafil offers proven quality-of-life benefits with a modest and manageable risk profile, while its role in extending healthy lifespan remains a plausible but unproven idea.

**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**